Clinical trials: H1N1/Influenza Infection
H1N1/2009 Influenza
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults
The purpose of this study is to assess the safety and effectiveness (immune response) to a licensed H1N12009 influenza vaccine in aboriginal children and adults.
- Trial name
- NCT01001026
- Testing
- Arepanrix
- Where
- 5 sites in Canada
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- David Scheifele
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy children.
- Trial name
- NCT00940108
- Testing
- CSL425
- Where
- 5 sites in Australia
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
The purpose of this study is to characterize the safety and immune response of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age.
- Trial name
- NCT00976820
- Testing
- GSK2340274A, GSK2340273A
- Where
- 30 sites in United States, Canada
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
H1N1 Influenza
Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial
The CHAT Pilot Trial is designed to compare rosuvastatin against placebo in patients with suspected H1N1. The pilot study will assess the feasibility of our clinical protocols, and study procedures.
- Trial name
- CHAT Pilot (NCT01798602)
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Canadian Critical Care Trials Group